<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT02222428</url>
  </required_header>
  <id_info>
    <org_study_id>1256.3</org_study_id>
    <nct_id>NCT02222428</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Pharmacokinetics of the Fixed Dose Combination of BI 1744 CL Plus BI 54903 XX Via Respimat® B Versus the Mono Products of BI 1744 CL Via Respimat® A and BI 54903 XX Via Respimat® B in Healthy Male and Female Volunteers</brief_title>
  <official_title>An Open Label, Randomised, Three-way Crossover Phase I Study to Assess Safety, Tolerability and Pharmacokinetics of the Fixed Dose Combination of BI 1744 CL Plus BI 54903 XX Via Respimat® B Versus the Mono Products of BI 1744 CL Via Respimat® A and BI 54903 XX Via Respimat® B in Healthy Male and Female Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The primary objective of this study was to compare the systemic exposure of BI 1744 BS and CD&#xD;
      1857 XX (the active metabolite of the pro-drug BI 54903 XX) at steady state following&#xD;
      inhalation of the fixed dose combination (FDC) of 6.2 μg BI 1744 CL plus 727.3 μg BI 54903 XX&#xD;
      (as ethanolic solution for inhalation, EIS) with the systemic exposure following inhalation&#xD;
      of the mono compounds of 10 μg BI 1744 CL (as aqueous solution for inhalation, AIS) and 727.3&#xD;
      μg BI 54903 XX (EIS), respectively, when administered once-daily via Respimat® Inhaler&#xD;
      (Respimat® A for AIS and Respimat® B for EIS) for 14 days in healthy volunteers. Secondary&#xD;
      objectives were to compare exposure to BI 1744 BS and CD 1857 XX after a single dose of the&#xD;
      BI 1744 CL/BI 54903 XX (6.2 μg/727.3 μg) FDC and the mono compounds, respectively; to compare&#xD;
      exposure to BI 54903 XX after a single dose and at steady state after multiple doses of the&#xD;
      BI 1744 CL/BI 54903 XX (6.2 μg/727.3 μg) FDC and the mono compounds, respectively; to compare&#xD;
      the safety and tolerability of BI 1744 CL and BI 54903 XX when administered as BI 1744 CL/BI&#xD;
      54903 XX (6.2 μg/727.3 μg) FDC and as the mono compounds, respectively.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC0-t,ss (area under the concentration time curve of the analyte in plasma from 0 to time t at steady state)</measure>
    <time_frame>up to 24 hours after drug administration</time_frame>
    <description>for BI 1744 BS and CD 1857 XX</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax,ss (maximum measured concentration of the analyte in plasma at steady state)</measure>
    <time_frame>up to 24 hours after drug administration</time_frame>
    <description>for BI 1744 BS and CD 1857 XX</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC0-t (area under the concentration time curve of the analyte in plasma from 0 to time t)</measure>
    <time_frame>up to 24 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax (maximum measured concentration of the analyte in plasma)</measure>
    <time_frame>up to 24 hours after drug administration</time_frame>
    <description>for BI 54903 XX</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cpre (pre-dose concentration of the analyte in plasma (at steady state)</measure>
    <time_frame>up to 24 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCt1-t2 (area under the concentration time curve of the analyte in plasma over the time interval t1 to t2)</measure>
    <time_frame>up to 24 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point)</measure>
    <time_frame>up to 24 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCτ (area under the plasma concentration-time curve over a uniform dosing interval τ)</measure>
    <time_frame>up to 24 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-∞ (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)</measure>
    <time_frame>up to 24 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>%AUCtz-∞ (the percentage of the AUC0-∞ that is obtained by extrapolation)</measure>
    <time_frame>up to 24 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax (time from dosing to the maximum concentration of the analyte in plasma)</measure>
    <time_frame>up to 24 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>λz (terminal rate constant of the analyte in plasma)</measure>
    <time_frame>up to 24 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t½ (terminal half-life of the analyte in plasma)</measure>
    <time_frame>up to 24 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRTih (mean residence time of the analyte in the body after inhaled administration)</measure>
    <time_frame>up to 24 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aet1-t2 (amount of the analyte that is eliminated in urine from the time point t1 to time point t2)</measure>
    <time_frame>up to 24 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fet1-t2 (fraction of the analyte eliminated in urine from time point t1 to time point t2)</measure>
    <time_frame>up to 24 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CLR,t1-t2 (renal clearance of the analyte from the time point t1 until the time point t2)</measure>
    <time_frame>up to 24 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F (apparent clearance of the analyte in the plasma after extravascular administration)</measure>
    <time_frame>up to 24 hours after drug administration</time_frame>
    <description>For BI 1744 BS and BI 54903 XX only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vz/F (apparent volume of distribution of the analyte during the terminal phase following an extravascular dose)</measure>
    <time_frame>up to 24 hours after drug administration</time_frame>
    <description>For BI 1744 BS and BI 54903 XX only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>up to 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of tolerability by investigator on 4-point scale</measure>
    <time_frame>28 days after each treatment period</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment>36</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>BI 1744 CL/BI 54903 XX FDC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 54903 XX</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 1744 CL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 1744 CL/BI 54903 XX FDC</intervention_name>
    <arm_group_label>BI 1744 CL/BI 54903 XX FDC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 54903 XX</intervention_name>
    <arm_group_label>BI 54903 XX</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 1744 CL</intervention_name>
    <arm_group_label>BI 1744 CL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy males and females according to the following criteria: Based upon a complete&#xD;
             medical history, including the physical examination, vital signs (Blood pressure (BP),&#xD;
             Pulse Rate (PR)), 12-lead Electrocardiogram (ECG), clinical laboratory tests&#xD;
&#xD;
          -  Age &gt;= 21 and Age &lt;= 50 years&#xD;
&#xD;
          -  Body mass index (BMI) &gt;= 18.5 and &lt;= 29.9 kg/m2&#xD;
&#xD;
          -  Signed and dated written informed consent prior to admission to the study in&#xD;
             accordance with Good Clinical Practice (GCP) and the local legislation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any finding of the medical examination (including Blood pressure (BP), Pulse Rate (PR)&#xD;
             and Electrocardiogram (ECG)) deviating from normal and of clinical relevance&#xD;
&#xD;
          -  Any evidence of a clinically relevant concomitant disease&#xD;
&#xD;
          -  Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,&#xD;
             immunological or hormonal disorders&#xD;
&#xD;
          -  Surgery of the gastrointestinal tract (except appendectomy)&#xD;
&#xD;
          -  Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or&#xD;
             neurological disorders&#xD;
&#xD;
          -  History of relevant orthostatic hypotension, fainting spells or blackouts&#xD;
&#xD;
          -  Chronic or relevant acute infections&#xD;
&#xD;
          -  History of relevant allergy/hypersensitivity (including allergy to drug or its&#xD;
             excipients)&#xD;
&#xD;
          -  Intake of drugs with a long half-life (&gt;24 h) within at least 1 month or less than 10&#xD;
             half-lives of the respective drug prior to administration or during the trial&#xD;
&#xD;
          -  Use of drugs which might reasonably influence the results of the trial or that prolong&#xD;
             the QT/QTc interval based on the knowledge at the time of protocol preparation within&#xD;
             10 days prior to administration or during the trial&#xD;
&#xD;
          -  Participation in another trial with an investigational drug within 2 months prior to&#xD;
             administration or during the trial&#xD;
&#xD;
          -  Smoker (&gt;10 cigarettes or &gt;3 cigars or &gt;3 pipes/day)&#xD;
&#xD;
          -  Inability to refrain from smoking on trial days&#xD;
&#xD;
          -  Alcohol abuse (more than 40 g/day)&#xD;
&#xD;
          -  Drug abuse&#xD;
&#xD;
          -  Blood donation (more than 100 mL within 4 weeks prior to administration or during the&#xD;
             trial)&#xD;
&#xD;
          -  Excessive physical activities (within 1 week prior to administration or during the&#xD;
             trial)&#xD;
&#xD;
          -  Any laboratory value outside the reference range of clinical relevance&#xD;
&#xD;
          -  Inability to comply with dietary regimen of trial site&#xD;
&#xD;
        For female subjects:&#xD;
&#xD;
          -  Pregnancy or planning to become pregnant within 2 months of study completion&#xD;
&#xD;
          -  Positive pregnancy test&#xD;
&#xD;
          -  No adequate contraception e.g., sterilization, intrauterine device (IUD), oral&#xD;
             contraception for at least 3 months prior to participation in the study&#xD;
&#xD;
          -  Inability to maintain this adequate contraception during the whole trial period&#xD;
&#xD;
          -  Lactation period&#xD;
&#xD;
          -  Asthma or history of pulmonary hyperreactivity&#xD;
&#xD;
          -  Hyperthyrosis&#xD;
&#xD;
          -  Allergic rhinitis in need of treatment&#xD;
&#xD;
          -  Clinically relevant cardiac arrhythmia&#xD;
&#xD;
          -  Bacterial and viral infections of the lung including tuberculosis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>August 2014</verification_date>
  <study_first_submitted>August 19, 2014</study_first_submitted>
  <study_first_submitted_qc>August 19, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 21, 2014</study_first_posted>
  <last_update_submitted>August 19, 2014</last_update_submitted>
  <last_update_submitted_qc>August 19, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 21, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olodaterol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT02222428
org study id: 1256.3
nct id: NCT02222428
lead sponsor: 
The primary objective of this study was to compare the systemic exposure of BI 1744 BS and CD
      1857 XX (the active metabolite of the pro-drug BI 54903 XX) at steady state following
      inhalation of the fixed dose combination (FDC) of 6.2 μg BI 1744 CL plus 727.3 μg BI 54903 XX
      (as ethanolic solution for inhalation, EIS) with the systemic exposure following inhalation
      of the mono compounds of 10 μg BI 1744 CL (as aqueous solution for inhalation, AIS) and 727.3
      μg BI 54903 XX (EIS), respectively, when administered once-daily via Respimat® Inhaler
      (Respimat® A for AIS and Respimat® B for EIS) for 14 days in healthy volunteers. Secondary
      objectives were to compare exposure to BI 1744 BS and CD 1857 XX after a single dose of the
      BI 1744 CL/BI 54903 XX (6.2 μg/727.3 μg) FDC and the mono compounds, respectively; to compare
      exposure to BI 54903 XX after a single dose and at steady state after multiple doses of the
      BI 1744 CL/BI 54903 XX (6.2 μg/727.3 μg) FDC and the mono compounds, respectively; to compare
      the safety and tolerability of BI 1744 CL and BI 54903 XX when administered as BI 1744 CL/BI
      54903 XX (6.2 μg/727.3 μg) FDC and as the mono compounds, respectively.
allocation: Randomized
intervention model: Crossover Assignment
primary purpose: Treatment
masking: None (Open Label)
measure: AUC0-t,ss (area under the concentration time curve of the analyte in plasma from 0 to time t at steady state)
time frame: up to 24 hours after drug administration
description: for BI 1744 BS and CD 1857 XX
measure: Cmax,ss (maximum measured concentration of the analyte in plasma at steady state)
time frame: up to 24 hours after drug administration
description: for BI 1744 BS and CD 1857 XX
measure: AUC0-t (area under the concentration time curve of the analyte in plasma from 0 to time t)
time frame: up to 24 hours after drug administration
measure: Cmax (maximum measured concentration of the analyte in plasma)
time frame: up to 24 hours after drug administration
description: for BI 54903 XX
measure: Cpre (pre-dose concentration of the analyte in plasma (at steady state)
time frame: up to 24 hours after drug administration
measure: AUCt1-t2 (area under the concentration time curve of the analyte in plasma over the time interval t1 to t2)
time frame: up to 24 hours after drug administration
measure: AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point)
time frame: up to 24 hours after drug administration
measure: AUCτ (area under the plasma concentration-time curve over a uniform dosing interval τ)
time frame: up to 24 hours after drug administration
measure: AUC0-∞ (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)
time frame: up to 24 hours after drug administration
measure: %AUCtz-∞ (the percentage of the AUC0-∞ that is obtained by extrapolation)
time frame: up to 24 hours after drug administration
measure: tmax (time from dosing to the maximum concentration of the analyte in plasma)
time frame: up to 24 hours after drug administration
measure: λz (terminal rate constant of the analyte in plasma)
time frame: up to 24 hours after drug administration
measure: t½ (terminal half-life of the analyte in plasma)
time frame: up to 24 hours after drug administration
measure: MRTih (mean residence time of the analyte in the body after inhaled administration)
time frame: up to 24 hours after drug administration
measure: Aet1-t2 (amount of the analyte that is eliminated in urine from the time point t1 to time point t2)
time frame: up to 24 hours after drug administration
measure: fet1-t2 (fraction of the analyte eliminated in urine from time point t1 to time point t2)
time frame: up to 24 hours after drug administration
measure: CLR,t1-t2 (renal clearance of the analyte from the time point t1 until the time point t2)
time frame: up to 24 hours after drug administration
measure: CL/F (apparent clearance of the analyte in the plasma after extravascular administration)
time frame: up to 24 hours after drug administration
description: For BI 1744 BS and BI 54903 XX only
measure: Vz/F (apparent volume of distribution of the analyte during the terminal phase following an extravascular dose)
time frame: up to 24 hours after drug administration
description: For BI 1744 BS and BI 54903 XX only
measure: Number of patients with adverse events
time frame: up to 16 weeks
measure: Assessment of tolerability by investigator on 4-point scale
time frame: 28 days after each treatment period
arm group label: BI 1744 CL/BI 54903 XX FDC
arm group type: Experimental
arm group label: BI 54903 XX
arm group type: Active Comparator
arm group label: BI 1744 CL
arm group type: Active Comparator
intervention type: Drug
intervention name: BI 1744 CL/BI 54903 XX FDC
arm group label: BI 1744 CL/BI 54903 XX FDC
intervention type: Drug
intervention name: BI 54903 XX
arm group label: BI 54903 XX
intervention type: Drug
intervention name: BI 1744 CL
arm group label: BI 1744 CL
criteria: 
gender: All
minimum age: 21 Years
maximum age: 50 Years
healthy volunteers: Accepts Healthy Volunteers
url: http://trials.boehringer-ingelheim.com
description: Related Info
responsible party type: Sponsor
mesh term: Olodaterol